4512.T
WAKAMOTO PHARMACEUTICAL CO.,LTD.
スタンダード · 医薬品 · 医薬品 · JP
JPY 306.00
−0.97%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 9.3B | 9.9B | 7.8B | 7.7B | 8.7B |
| Cost of Revenue | 1.1B | 5.2B | 4.2B | 4.1B | 4.6B |
| Gross Profit | 1.0B | 4.7B | 3.6B | 3.6B | 4.1B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 1.2B | 4.5B | 4.1B | 3.8B | 4.0B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.2B | 4.5B | 4.1B | 3.8B | 4.0B |
| Cost and Expenses | 9.2B | 9.7B | 8.2B | 7.9B | 8.5B |
| Operating Income (EBIT) | 71.0M | 255.0M | (457.0M) | (195.0M) | 141.0M |
| Non-Operating | |||||
| Interest Income | — | 2.6M | 1.4M | 29.0K | 28.0K |
| Interest Expense | 280.0K | 1.9M | 882.0K | 531.0K | 578.0K |
| Net Interest Income | — | 691.0K | 549.0K | (502.0K) | (550.0K) |
| Other Non-Op Income/Expense | 25.8M | 853.0K | 48.6M | 33.7M | 101.1M |
| Non-Operating Income (excl Interest) | 3.6M | 67.1M | 63.0M | 70.6M | 118.6M |
| EBT (Pre-Tax Income) | (117.5M) | 256.4M | 7.5M | 158.9M | 211.6M |
| Income Tax Expense | (9.0M) | 29.2M | (57.0M) | 49.9M | 73.3M |
| Bottom Line | |||||
| Net Income | 298.0M | 227.0M | 64.0M | 108.0M | 138.0M |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 298.0M | 227.0M | 64.0M | 108.0M | 138.0M |
| Per Share | |||||
| Basic EPS | ¥9 | ¥7 | ¥2 | ¥3 | ¥4 |
| Diluted EPS | ¥9 | ¥7 | — | — | — |
| Revenue Per Share | ¥268 | ¥285 | ¥224 | ¥223 | ¥250 |
| Shares | |||||
| Basic Shares Outstanding | 34.7M | 34.7M | 34.7M | 34.7M | 34.7M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 697.9M | (26.7M) | 216.6M | 586.8M |
| D&A | — | 442.9M | 430.3M | 411.6M | 445.8M |
| EBIT | 71.0M | 255.0M | (457.0M) | (195.0M) | 141.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026